Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

CRANBURY, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the second quarter 2009.

On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.60 per share ($0.51 per share on a non-GAAP basis) for the three months ended June 30, 2009. As of June 30, 2009, cash, cash equivalents, and marketable securities totaled $100.4 million.

John F. Crowley, President and CEO of Amicus stated, "The second quarter was marked by a significant achievement for Amicus with our lead program, Amigal for Fabry disease, entering Phase 3 development." Crowley continued, "This is a major step for the Company as we have now transitioned to a late-stage biopharmaceutical company and are one step closer to bringing to market an important, novel treatment to patients who suffer with Fabry disease."

Clinical Program Updates

Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease

In the second quarter of 2009, Amicus announced that the Company reached agreement with the U.S. Food and Drug Administration (FDA) on the key protocol design elements of its pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. Amicus has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of th
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... information — Global biopharmaceutical company UCB, Inc. and professional ... of a new Pledge campaign for people with epilepsy ... empowers the millions of Americans living with epilepsy ... to demand more: greater understanding of the condition, better ... seizure control.  More information is available at www.ourtimeourpledge.com ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
Breaking Biology Technology:Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... N.J. and WORCESTER, Mass., April 25, 2012  Quest Diagnostics ... of diagnostic testing, information and services, today announced a ... unit, a leader in neurology diagnostics, for amyotrophic lateral ... It is the first clinically available testing ...
...  A well-respected, independent, third-party laboratory has tested for Tuberculosis ... BNP (BioNanoPore) test kits and achieved the detection ... Standard culture times for conventional technologies take a minimum ... In concurrent tests for TB at the same facility, ...
... 2012 AMRI (NASDAQ: AMRI ) announced ... functions. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ... teams are being combined into one functional sales organization, ... promoted to Vice President, Business Development, North America. This ...
Cached Biology Technology:Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 2Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease) 3NanoLogix Provides Testing and Operations Update 2NanoLogix Provides Testing and Operations Update 3AMRI Strengthens Business Development and Marketing Groups 2AMRI Strengthens Business Development and Marketing Groups 3
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
(Date:6/17/2013)... their food may turn out to be just as important ... of St. Michael,s Hospital. , The study, led by ... association between poor eating habits in kids ages three to ... cholesterol, putting them at risk for cardiovascular disease later in ... Medical Association Journal today. , "We know that ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2Poor eating behaviors may put preschoolers at risk for later health problems 2
... toxins that affect human health and ecosystems in smoke ... also suggest that smoldering fires may produce more toxins ... to a minimum during controlled burns. Finding ... understand how they cycle through earth and air. Smoke-related ...
... Pacific Northwest National Laboratory will be home to one ... earlier this week by the White House in conjunction ... the annual meeting of the National Academy of Sciences. ... research on energy, are being established by the DOE,s ...
... a remote-controlled camera on the Tahoe National Forest in ... populations, according to a team of 10 federal, state ... the latest edition of Northwest Science and ... first scientifically verified California wolverine in 86 years. The ...
Cached Biology News:Potentially harmful chemicals found in forest fire smoke 2DOE to establish Energy Frontier Research Center at PNNL 2DOE to establish Energy Frontier Research Center at PNNL 3Origins of wolverine in California genetically verified 2
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
... robotic system and disposable ESI Chip allow ... capabilities of electrospray mass spectrometers for life ... allows users to either speed analysis for ... mapping applications, or long acquisition times for ...
... Pulsed Dynamic Focusing MALDI (PDF-MALDI) source provides ... that do not need online separation. Paired ... LC/MS and Agilents powerful Spectrum Mill software, ... analysis of 2D gel-spot digests. It provides ...
... is an all-in-one rotator/rocker with a ... different mixing motions: rotating, rocking/shaking, ... as a combination of all these ... of the Vibraotme Roto-Shake Genie consists ...
Biology Products: